Rationally designed FPTase inhibitors

Drugs of the Future

Volumn 22, Issue 10, 1997, Pages 1133-1146

  Halazy, S ^a,b   Gotteland, J P ^a   Lamothe, M ^a   Perrin, D ^a   Hill, B T ^a  

^a Division of Medicinal Chemistry IV

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; ANTINEOPLASTIC AGENT; B 581; BMS 184382; BMS 186511; BMS 188031; BMS 188222; BMS 192331; BMS 192846; BMS 193269; BMS 193970; FTI 265; GTI 286; GTI 287; L 731734; L 731735; L 745631; N (8 AMINO 2 BENZYL 5 ISOPROPYL 9 MERCAPTO 3,6 NONADIENOYL)METHIONINE; N (8 AMINO 2 BENZYL 5 ISOPROPYL 9 MERCAPTO 3,6 NONADIENOYL)METHIONINE METHYL ESTER; N [2 [2 (2 AMINO 3 MERCAPTOPROPYLAMINO) 3 METHYLPENTYLOXY] 3 PHENYLPROPIONYL]METHIONINE SULFONE; N [2 [2 (2 AMINO 3 MERCAPTOPROPYLAMINO) 3 METHYLPENTYLOXY] 3 PHENYLPROPIONYL]METHIONINE SULFONE METHYL ESTER; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RPR 113829; UNCLASSIFIED DRUG;

CANCER RESEARCH; CHEMICAL MODIFICATION; DRUG ACTIVITY; DRUG DESIGN; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME MECHANISM; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; REVIEW;

EID: 0031452415     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Boguski, M.S., McCormick, F. Proteins regulating ras and its relatives. Nature 1993, 366: 643-54.
2. Barbacid, M. Ras genes. Ann Rev Biochem 1987, 56: 779-827.
3. Bos, J.L. Ras oncogenesin human cancer: A review. Cancer Res 1989,49:4682-9.
4. Abrams, S.I., Hand, P.H., Tsang, K.Y., Schlom, J. Mutant ras epitopes as targets for cancer vaccines. Semin Oncol 1996, 23: 118-34.
5. Rak, J., Mitsuhashi, Y., Erdos, V., Huang, S.N., Filmus, J., Kerbel, R.S. Massive programmed cell death in intestinal epithelial cells induced by three-dimensional growth conditions: Suppression by mutant c-H-ras oncogene expression. J Cell Biol 1995, 131: 1587-98.
6. Perrin, D., Halazy, S., Hill, B.T. Inhibitors of the ras signal transduction pathway as potential antitumor agents. J Enzyme Inhib 1996,11:77-95.
7. Cox, A.D., Der, C.J. Protein prenylation: Key to ras oncogenicity? CurrOpin Cell Biol 1992, 4:1008-16.
8. Zhang, F.L., Casey, P.J. Protein prenylation: Molecular mechanisms and functional consequences. Ann Rev Biochem 1996, 65: 241-69.
9. Boyartchuk, V.L., Ashby, M.N., Rine, J. Modulation of ras and a-factor function by carboxyl-terminalproteolysis. Science 1997, 275:1796-800.
10. Liu, L, Dudler, T., Gelb, M.H. Purification ofa protein palmitoyltransferase that acts on H-ras protein and on a C-terminal N-ras peptide. J Biol Chem 1996, 271: 23269-76.
11. Brown, M.S., Goldstein, J.L. Protein prenylation. Mad bet for Rab. Nature 1993, 366:14-5.
12. Lebowitz, P.F., Davide, J.P., Prendergast, G.C. Evidence that farnesyltransferase inhibitors suppress Pas transformation by interfering with Rho activity. Mol Cell Biol 1995,15: 6613-22.
13. Sepp-Lorenzino, L, Ma, 2.P., Rands, E. etal. Peptidomimetic inhibitor of farnesyl protein transi'erase blocks the anchorage-dependent and-independent growth of human tumor cell lines. Cancer Res 1995, 55: 5302-9.
14. Cales, C.A., Michael, R.L, Stayrook, K.R. et al. Prenylation of oncogenic human PTPcaax protein tyrosine phosphatases. Cancer Lett 1996,110:49-55.
15. Buss, J.E., Masters, J.C. Jr. Farnesyl transferase inhibitors: The successes and surprises of a new class of potential cancer chemotherapeutics. Chem Biol 1995, 2: 787-91.
16. Levy, R. Farnesyl transferase inhibitors (anti-ras). A new class of anticancer drugs. Presse Med 1995, 24: 725-9.
17. Sebolt-Leopold, J.S. The therapeutic potential of ras-targeted protein farnesyltransferase inhibitors. Emerg Drugs 1996, 1: 219-39.
18. Graham, S.L. Inhibitors of protein farnesylation: A new approach to cancer chemotherapy. Exp Opin Ther Pat 1995, 5: 1269-85.
19. Hamilton, A.D., Sebti, S.M. Inhibitors of Ras farnesyltransferase as novel antitumor agents. Drug News Perspect 1995, 8: 138-45.
20. Ayral-Kaloustian, S., Skotnicki, J.S. Ras farnesyltransferase inhibitors. Annu Rep Med Chem 1996, 31:171 -80.
21. Graham, S.L., Williams, T.M. Inhibitors of protein farnesylation. Exp Opin Ther Pat 1996, 6:1295-304.
22. Gibbs, J.B., Kohl, N.E., Koblan, K.S. et al. Farnesyltransferase inhibitors and anti-Ras therapy. Breast Cancer Res Treat 1996,38: 75-83.
23. Koblan, K.S., Kohl, N.E., Orner, C.A. et al. Farnesyltransferase inhibitors: a new class of cancer chemotherapeutics. Biochem Soc Trans 1996, 24:688-92.
24. Der, C.J., Cox, A.D., Sebti, S.M., Hamilton, A.D. Farnesyltransferase inhibitors: Anti-Ras drugs for cancer'treatment?'Anti-Cancer Drugs 1996, 7:165-72.
25. Hiwasa, T. Has inhibitors. Oncol Rep 1996,3:7-14.
26. Singh, S.B., Lingham, R.B. Farnesyt-protein transferase inhibitors in early development. Exp Opin Invest Drugs 1996,5:1589-99.
27. Lerner, E.C., Hamilton, A.D., Sebti, S.M. Inhibition of ras prenylation: A signaling target for novel anti-cancer drug design. AntiCancer Drug Des 1997,12: 229-38.
28. Huang, C.C., Casey, P.J., Fierke, C.A. Evidence fora catalytic role of zinc in protein farnesyltransferase: Spectroscopy of Co2+-farnesyltransferase indicates metal coordination of the substrate thiolate. J Biol Chem 1997, 272: 20-3.
29. Park, H.W., Boduluri, S.R., Moomaw, J.F., Casey, P.J., Beese, L.S. Crystal structure of protein farnesyltransferase at 2.25 angstrom resolution. Science 1997, 275:1800-4.
30. Fu, H.W., Moomaw, J.F., Moomaw, C.R., Casey, P.J. Identification of a cysteine residue essential for activity of protein farnesyltransferase: Cys-299 is exposed only upon removal of zinc from the enzyme. J Biol Chem 1997, 271: 28541-8.
31. Stradley, S.J., Rizo J., Gierasch, L.M. Conformation of a heptapeptide substrate bound to protein farnesyltransferase. Biochemistry 1993, 32: 12586-90.
32. Koblan, K.S., Culberson, J.C., Desolms, S.J. et al. NMRstudies of novel inhibitors bound to farnesyl-protein transferase. Protein Sei 1995, 4: 681-8.
33. Pompliano, D.L, Rands, E., Schaber, M.D., Mosser, S.D., Anthony, N.J., Gibbs, J.B. Steady state kinetic mechanism of Pas farnesyl: Protein transferase. Biochemistry 1992,31:3800-7.
34. Furfine, E.S., Leban, J.J., Landavazo, A., Moomaw, J.F., Casey, P.J. Protein farnesyltransferase: Kinetics of farnesyl pyrophosphate binding and product release. Biochemistry 1995, 34: 6857-62.
35. Dolence, J.M., Cassidy, P.B., Mathis, J.R., Poulter, C.D. Yeast protein farnesyltransferase: Steady-state kinetic studies of substrate binding. Biochemistry 1995, 34:16687-94.
36. Pompliano, D.L., Schaber, M.D., Mosser, S.D., Orner, C.A., Shafer, J.A., Gibbs, J.B. Isoprenoid diphosphate utilization by recombinant human farnesyl:protein transferase: Interactive binding between substrates and a preferred kinetic pathway. Biochemistry 1993, 32: 8341-7.
37. Casey, P.J., Seabra, M.C. Protein prenyltransferases. J Biol Chem 1996, 271:5289-92.
38. Tschantz, W.R., Furfine, E.S., Casey, P.J. Substrate binding is required for release of product from mammalian protein farnesyltransferase. J Biol Chem 1997, 272: 9989-93.
39. Dolence, J.M., Poulter, C.D. A mechanism forposttranslational modifications of proteins by yeast protein farnesyltransferase. Proc Natl Acad Sei USA 1995, 92: 5008-11.
40. Mu, Y.Q., Orner, C.A., Gibbs, R.A. On the stereochemical course of human protein-farnesyl transferase. J Am Chem Soc 1996, 118:1817-23.
41. Kumar, A., Beresini, M.H., Dhawan, P., Mehta, K.D. a-Subunit of farnesyltransferase is phosphorylated in vivo: Effect of protein phosphatase-1 on enzymatic activity. Biochem Biophys Res Commun 1996,222:445-52.
42. Wang, T.W., Danielson, P.D., Li, B.Y., Shah, P.C., Kim, S.D., Donahoe, P.K. The p21ras farnesyltransferase alpha subunit in TGF-beta andactivin signaling. Science 1996,271:1120-2.
43. Ventura, F., Liu, F., Doody, J., Massagué, J. Interaction of transforming growth factor-beta receptor I with farnesyl-protein transfer-ase-alpha in yeast and mammalian cells. J Biol Chem 1996, 271: 13931-4.
44. Del Villar, K., Mitsuzawa, H., Yang, W., Sattler, I., Tamanoi, F. Am/no acid substitutions that convert the protein substrate specificity of farnesyltransferase to that of geranylgeranyltransferase type I. J Biol Chem 1997, 272: 680-7.
45. Zhang, F.L., Fu, H.W., Casey, P.J., Bishop, W.R. Substitution of cadmium for zinc in farnesyl:protein transferase alters its substrate specificity. Biochemistry 1996, 35: 8166-71.
46. Lerner, E.G., Qian, Y., Hamilton, A.D., Sebti, S.M. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor. J Biol Chem 1995, 270: 26770-3.
47. Yokoyama, K., Zimmerman, K., Scholten, J., Gelb, M.H. Differentialprenylpyrophosphate binding to mammalian protein geranylgeranyltransferase-l and protein farnesyltransferase and its consequence on the specificity of protein prenylation. JBiolChem1997, 272: 3944-52.
48. Osman, H., Mazet, J.L., Maume, G., Maume, B.F. Geranylgeranyl as well as farnesyl moiety is transferred to ras p21 overproduced in adrenocortical cells transformed by c-ha-ras-ejoncogene. Biochem Biophys Res Commun 1997, 231:789-92.
49. Zhang, F.L., Kirschmeier, P., Carr, D. et al. Characterization of Ha-Ras, N-Ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type 1. J Biol Chem 1997, 272:10232-9.
50. Reiss, Y., Goldstein, J.L., Seabra, M.C., Casey, P.J., Brown, M.S. Inhibition of purified p2Iras farnesyl:protein transferase by Cys-AAX tetrapeptides. Cell 1990, 62: 81-8.
51. Goldstein, J.L., Brown M.S., Stradley, S.J., Reiss, Y, Gierasch, L.M. Nonfarnesylated tetrapeptide inhibitors of protein farnesyltransferase. J Biol Chem 1991, 266:15575-8.
52. Brown, M.S.,GoIdstein, J.L, Paris, K.J., Burnier, J.P., Marsters, U.C. Jr. Tetrapeptide inhibitors of protein farnesyltransferase: Amino-termihal substitution in phenylalanine-containing tetrapeptides restores farnesylation. Proc Natl Acad Sei USA 1992,89:8313-6.
53. Kohl, N.E., Mosser, S.D., DeSolms, S.J. et al. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 1993, 260:1934-7.
54. Graham, S.L., Gibbs, J.B., Pompliano, D.L. Pseudopeptide inhibitors of ras farnesyl-proteine transferase. J Med Chem 1994, 37:725-32.
55. Kohl, N.E., Wilson, F.R., Mosser, S.D. et al. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sei USA 1994, 91: 9141-5.
56. Kohl, N.E., Orner, C.A., Conner, M.W. et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med 1995,1:792-7.
57. Garcia, A.M., Rowell, C., Ackermann, K., Kowalczyk, J.J., Lewis, M.D. Peptidomimetic inhibitors of ras farnesylation and function in whole cells. J Biol Chem 1993, 268:18415-8.
58. Cox, A.D., Garcia, A.M., Westwick, J.K. et al. The CAAXpeptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic Ras signaling and transformation. J Biol Chem 1994, 269:19203-6.
59. Nagasu, T., Yoshimatsu, K., Rowell, C., Lewis, M.D., Garcîa, A.M. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res 1995, 55: 5310-4.
60. James, G.L., Goldstein, J.L., Brown, M.S. etal. Benzodiazepine peptidomimetics: Potent inhibitors of Ras farnesylation in animal cells. Science 1993, 260:1937-42.
61. 61. Nigam, M., Seong, C.-M., Qian, Y, Hamilton, A.D., Sebti, S.M. Potent inhibition of human tumor p21ras farnesyltransferase by l A1A2-lackmgp21ras CA1A2Xpeptidomimetics. J Biol Chem 1993, 268:20695-8.
62. Qian, Y., Blaskovich, M.A., Saleem, M. et al. Design and structural requirements of potent peptidomimetic inhibitors of p21 ras farnesyltransferase. J Biol Chem 1994, 269:12410-3.
63. Qian, Y, Blaskovich, M.A., Seong, C.-M., Vogt, A., Hamilton, A.D. ,Sebti,S.M. Peptidomimetic inhibitors ofp21 ras farnesyltransferase: Hydrophobie functionalization leads to disruption ofp21ras membrane association in whole cells. Bioorg Med Chem Lett 1994, 4: 2579-84.
64. Vogt, A., Qian, Y, Blaskovich, M.A., Possum, R.D., Hamilton, A.D., Sebti, S.M. A non-peptide mimetic of Ras-CAAX: Selective inhibition of famesyltransferase and Ras processing. J Biol Chem 1995,270:660-4.
65. Sun, J., Qian, Y, Hamilton, A.D., Sebti, S.M. Ras CAAXpeptidomimetic FT/ 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res 1995, 55: 4243-7.
66. Qian, Y, Vogt, A., Sebti, S.M., Hamilton, A.D. Design and synthesis of non-peptide Ras CAAX mimetics as potent famesyltransferase inhibitors. J Med Chem 1996, 39: 217-23.
67. Dinsmore, C.J., Williams, T.M., Hamilton, K. et al. Diarylether inhibitors of farnesyl-protein transferase. Bioorg Med Chem Lett 1997,7:1345-8.
68. Burns, C.J., Guitton, J.-D., Baudoin, B. et al. Novelconformationally extended naphthalene-based inhibitors of famesyltransferase. J Med Chem 1997, 40:1763-7.
69. Leftheris, K., Kline, T., Vite, G.D. et al. Development of highly potent inhibitors of Ras famesyltransferase possessing cellular and m vivo activity. J Med Chem 1996, 39: 224-36.
70. Leftheris, K., Cho, Y.H., Vite, G.D. et al. Highly potent thiolbased inhibitors of ras famesyltransferase. 25th Natl Med Chem Symp (June 18-12, Ann Harbor, Ml) 1996, Abst.11.
71. Clerc, F.F., Guitton, J.-D., Fromage, N. et al. Constrained analogs ofKCVFM with improved inhibitory properties against farnesyl transferase. Bioorg Med Chem Lett 1995, 5:1779-84.
72. Harrington, E.M., Kowalczyk, J.J., Pinnow, S.L., Ackermann, K., Garcia, A.M., Lewis, M.D. Cysteine and methionine linked by carbon pseudopeptides inhibit farnesyl transferase. Bioorg Med Chem Lett 1994,4: 2775-80.
73. Williams, T.M.,Ciccarone, T.M.,MacTough, S.C. et al.2-Substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of famesyltransferase. J Med Chem 1996, 39:1345-8.
74. Kowalczyk, J.J., Ackermann, K., Garcfa, A.M., Lewis, M.D. Phenolic replacements for cysteine in farnesyl transferase inhibitors based on CVFM. Bioorg Med Chem Lett 1995, 5: 3073-8.
75. Patel, D., Patel, M.M., Robinson, S.S., Gordon, E.M. Phenol based tripeptide inhibitors of ras farnesyl protein transferase. Bioorg Med Chem Lett 1994, 4:1883-8.
76. Hunt, J.T., Lee, V.G., Leftheris, K. et al. Potent, cell active, nonthiol tetrapeptide inhibitors of farnesyltransferase. J Med Chem 1996,39:353-8.
77. McClard, R.W., Fujita, T.S., Stremler, K.E., Poulter, C.D. Novel phosphonylphosphinyl (P-C-P-C-) analogues of biochemically interesting diphosphates. Syntheses and properties of P-C-P-Canalogues of isopentenyl diphosphate and dimethylallyl diphosphate. J Am Chem Soc 1987,109: 5544-5.
78. Biller, S.A., Forster, C., Gordon, E.M., Harrity, T., Scott, W.A., Ciosek, C.P., Jr. Isoprenoid (phosphinylmethyl)phosphonates as inhibitors ofsqualene synthetase. J Med Chem 1988,31:1869-71.
79. Gibbs, J.B., Pompliano, D.L., Mosser, S.D. et al. Selective inhibition of farnesyl-protein transferase blocks Ras processing in vivo. J Biol Chem 1993, 268: 7617-20.
80. Kang, M.S., Stemerick, D.M., Zwolshen, J.H., Harry, B.S., Sunkara, P.S., Harrison, B.L. Farnesyl-derived inhibitors of ras farnesyl transferase. Biochem Biophys Res Commun 1995,217: 245-9.
81. Mu, Y.Q., Gibbs, R.A., Eubanks L.M., Poulter, C.D. Cupratemediated synthesis and biological evaluation of cyclopropyl- and tert-butylfarnesyl diphosphate analogs. J Org Chem 1996, 61: 8010-5.
82. Cohen, LH.,Valentijn,A.R.P.M.,Roodenburg,Letal. Different analogues of farnesyl pyrophosphate inhibit squalene synthase and protein: farnesyltransferase to different extents. Biochem Pharmacol 1995, 49:839-45.
83. Valentijn, A.R.P.M., Van der Marel, G.A., Cohen, L.H., Van Boom, J.H. An expeditious synthesis of pyrophosphate analogues of farnesyl pyrophosphate using the phosphonylating agent methyl methylphosphonomorpholidate. Synlett 1991, 663-4.
84. Biller, S.A., Sofia, M.J., De Lange, B. et al. The first potent inhibitor of squalene synthase: A profound contribution of an ether oxygen to inhibitor-enzyme interaction. J Am Chem Soc 1991, 133: 8522-4.
85. Manne, V., Ricca, C.S., Brown, J.G. et al. Ras farnesylation as a target for novel antitumor agents: Potent and selective farnesyl diphosphate analog inhibitors of farnesyltransferase. Drug Dev Res 1995, 34: 121-37.
86. Patel, D.V., Schmidt, R.J., Biller, S.A., Gordon, E.M., Robinson, S.S., Manne, V. Farnesyl diphosphate-based inhibitors of ras farnesyl protein transferase. J Med Chem 1995, 38: 2906-21.
87. Lamothe, M., Perrin, D., Blotières, D. et al. Inhibition of farnesyl protein transferase by new farnesyl phosphonate derivatives of phenylalanine. Bioorg Med Chem Lett 1996, 6:1291-6.